Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry
- PMID: 30230952
- DOI: 10.1177/1352458518799580
Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry
Abstract
Background: Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease. Over time, symptoms accumulate leading to increased disability of patients.
Objective: The objective of this article is to analyze the prevalence of symptoms and symptomatic treatment patterns in a nationwide MS registry.
Methods: Data sets from 35,755 patients were analyzed.
Results: More than two-thirds of patients were women with a mean age of 46.1 (±12.8) years. Median Expanded Disability Status Score (EDSS) was 3.0. The most frequently reported symptoms were fatigue, spasticity, and voiding disorders. In patients with short disease duration, fatigue was reported most frequently. Symptomatic treatment was most common for spasticity and depression, whereas fatigue was treated only in a third of affected patients. Almost a fifth of patients with EDSS ⩽ 3.5 and neuropsychological symptoms had retired from work.
Conclusion: Whereas treatment for spasticity and depression is common in our cohort, sexual dysfunction, dysphagia, cognitive dysfunction, and fatigue are treated to a far lesser extent. The need for psychological support, physical, and occupational therapy has to be recognized as neuropsychological symptoms have a great impact on retirement at an early stage. Overall symptomatic treatment rates for the most common symptoms have increased over the last years (p < 0.001).
Keywords: Multiple sclerosis; disability progression; symptom manifestation; symptomatic treatment; symptoms.
Similar articles
-
Managing the symptoms of multiple sclerosis: a multimodal approach.Clin Ther. 2006 Apr;28(4):445-60. doi: 10.1016/j.clinthera.2006.04.005. Clin Ther. 2006. PMID: 16750459 Review.
-
Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry.Acta Neurol Scand. 2017 Apr;135(4):394-399. doi: 10.1111/ane.12612. Epub 2016 Jun 9. Acta Neurol Scand. 2017. PMID: 27283842
-
Need for symptomatic management in advanced multiple sclerosis.Acta Neurol Scand. 2017 May;135(5):529-532. doi: 10.1111/ane.12631. Epub 2016 Jun 29. Acta Neurol Scand. 2017. PMID: 27357364
-
A multimodal approach to managing the symptoms of multiple sclerosis.Neurology. 2004 Dec 14;63(11 Suppl 5):S12-8. doi: 10.1212/wnl.63.11_suppl_5.s12. Neurology. 2004. PMID: 15596731 Review.
-
Symptomatic therapy of multiple sclerosis.Curr Opin Neurol. 1994 Jun;7(3):229-33. doi: 10.1097/00019052-199406000-00009. Curr Opin Neurol. 1994. PMID: 8081516 Review.
Cited by
-
Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis.Pharmaceutics. 2023 Dec 19;16(1):3. doi: 10.3390/pharmaceutics16010003. Pharmaceutics. 2023. PMID: 38276481 Free PMC article.
-
Epileptic seizures at multiple sclerosis onset and their role in disease progression.Ther Adv Neurol Disord. 2023 Oct 6;16:17562864231192826. doi: 10.1177/17562864231192826. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37808247 Free PMC article.
-
Factors associated with depressive mood at the onset of multiple sclerosis - an analysis of 781 patients of the German NationMS cohort.Ther Adv Neurol Disord. 2023 Sep 8;16:17562864231197309. doi: 10.1177/17562864231197309. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37692259 Free PMC article.
-
Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study.Sci Rep. 2023 Sep 2;13(1):14480. doi: 10.1038/s41598-023-41271-6. Sci Rep. 2023. PMID: 37660223 Free PMC article.
-
Depression and Anxiety in Association with Polypharmacy in Patients with Multiple Sclerosis.J Clin Med. 2023 Aug 18;12(16):5379. doi: 10.3390/jcm12165379. J Clin Med. 2023. PMID: 37629420 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
